Getting to the stem of chronic myeloid leukaemia (original) (raw)

• Nowell, P. & Hungerford, D. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497–1499 (1960).
  Google Scholar
• Bartram, C. R. et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306, 277–280 (1983).
  Article CAS PubMed Google Scholar
• Frank, D. A. & Varticovski, L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 10, 1724–1730 (1996).
  CAS PubMed Google Scholar
• Krebs, D. L. & Hilton, D. J. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19, 378–387 (2001).
  Article CAS PubMed Google Scholar
• Neshat, M. S., Raitano, A. B., Wang, H. G., Reed, J. C. & Sawyers, C. L. The survival function of the Bcr–Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol. Cell Biol. 20, 1179–1186 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Neubauer, H. et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397–409 (1998).
  Article CAS PubMed Google Scholar
• Puil, L. et al. Bcr–Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13, 764–773 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Sattler, M. et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1, 479–492 (2002).
  Article CAS PubMed Google Scholar
• Sattler, M. et al. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol. Cell Biol. 19, 7473–7480 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S. & Cortes, J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med. 145, 913–923 (2006).
  Article PubMed Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
  Article CAS PubMed Google Scholar
• Einhorn, L. H. & Williams, S. D. The role of _cis_-platinum in solid-tumor therapy. N. Engl. J. Med. 300, 289–291 (1979).
  Article CAS PubMed Google Scholar
• Goldman, J., Gordon, M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk. Lymphoma 47, 1–7 (2006).
  Article CAS PubMed Google Scholar
• Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423–1432 (2003). This was the first large analysis to reveal lack of complete molecular response in majority of cytogenetic responses.
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myelogenous leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).
  Article CAS PubMed Google Scholar
• Roy, L. et al. Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108, 1478–1484 (2006).
  Article CAS PubMed Google Scholar
• Deininger, M. W., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343–3356 (2000).
  Article CAS PubMed Google Scholar
• Jiang, X., Saw, K. M., Eaves, A. & Eaves, C. Instability of BCR–ABL gene in primary and cultured chronic myeloid leukemia stem cells. J. Natl Cancer Inst. 99, 680–693 (2007).
  Article CAS PubMed Google Scholar
• Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014–1018 (2002).
  Article CAS PubMed Google Scholar
• Hochhaus, A. et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109, 2303–2309 (2007).
  Article CAS PubMed Google Scholar
• le Coutre, P. et al. Nilotinib (formerly AMN107), a highly selective BCR–ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111, 1834–1839 (2008).
  Article CAS PubMed Google Scholar
• Cortes, J., O'Brien, S. & Kantarjian, H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104, 2204–2205 (2004).
  Article CAS PubMed Google Scholar
• Usuki, K., Iijima, K., Iki, S. & Urabe, A. CML cytogenetic relapse after cessation of imatinib therapy. Leuk. Res. 29, 237–238 (2005).
  Article CAS PubMed Google Scholar
• Piazza, R. G. et al. Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. Leukemia 19, 1985–1987 (2005).
  Article CAS PubMed Google Scholar
• Kantarjian, H. et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103, 2873–2878 (2004).
  Article CAS PubMed Google Scholar
• Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531–2541 (2006).
  Article CAS PubMed Google Scholar
• Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542–2551 (2006).
  Article PubMed Google Scholar
• Kaeda, J., Chase, A. & Goldman, J. M. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol. 107, 64–75 (2002).
  Article CAS PubMed Google Scholar
• Kiel, M. J., He, S., Ashkenazi R., et al. Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU. Nature 449, 238–242 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Morrison, S. J., Hemmati, H. D., Wandycz, A. M. & Weissman, I. L. The purification and characterization of fetal liver hematopoietic stem cells. Proc. Natl Acad. Sci. USA 92, 10302–10306 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Murray, L. et al. Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin− subpopulation from mobilized peripheral blood. Blood 85, 368–378 (1995).
  Article CAS PubMed Google Scholar
• Uchida, N. & Weissman, I. L. Searching for hematopoietic stem cells: evidence that Thy-1.1lo Lin−Sca-1+ cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow. J. Exp. Med. 175, 175–184 (1992). One of a series of seminal early studies that edified the concept that flow cytometry could be used to prospectively isolate haematopoietic stem cells.
  Article CAS PubMed Google Scholar
• Kiel, M. J. et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109–1121 (2005).
  Article CAS PubMed Google Scholar
• Wolf, N. S., Kone, A., Priestley, G. V. & Bartelmez SH . In vivo and in vitro characterization of long-term repopulating primitive hematopoietic cells isolated by sequential Hoechst 33342-rhodamine 123 FACS selection. Exp. Hematol. 21, 614–622 (1993).
  CAS PubMed Google Scholar
• Morrison, S. J., Uchida, N. & Weissman, I. L. The biology of hematopoietic stem cells. Annu. Rev. Cell Dev. Biol. 11, 35–71 (1995).
  Article CAS PubMed Google Scholar
• Hogan, C. J., Shpall, E. J. & Keller, G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc. Natl Acad. Sci. USA 99, 413–418 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Dick, J. E., Bhatia, M., Gan, O., Kapp, U. & Wang, J. C. Assay of human stem cells by repopulation of NOD/SCID mice. Stem Cells 15 (Suppl. 1), 199–203; discussion 204–207 (1997).
  Article PubMed Google Scholar
• McKenzie, J. L., Gan, O. I., Doedens, M., Wang, J. C. & Dick, J. E. Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nature Immunol. 7, 1225–1233 (2006).
  Article CAS Google Scholar
• Hogge, D. E., Lansdorp, P. M., Reid, D., Gerhard, B. & Eaves, C. J. Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor. Blood 88, 3765–3773 (1996).
  Article CAS PubMed Google Scholar
• Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A. M. & Peault, B. Isolation of a candidate human hematopoietic stem-cell population. Proc. Natl Acad. Sci. USA 89, 2804–2808 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Yin, A. H. et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002–5012 (1997).
  Article CAS PubMed Google Scholar
• Moreb, J. S. et al. Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells. Leuk. Lymphoma 20, 77–84 (1995).
  Article CAS PubMed Google Scholar
• McKenzie, J. L., Takenaka, K., Gan, O. I., Doedens, M. & Dick, J. E. Low Rhodamine123 retention identifies long-term human hematopoietic stem cells within the Lin−CD34+CD38- population. Blood 109, 543–545 (2006).
  Article PubMed CAS Google Scholar
• Jamieson, C. H. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657–667 (2004). Jamieson et al . redefined the cancer stem cell model by illustrating the presence of stem cell-like qualities in committed progenitors of advanced disease.
  Article CAS PubMed Google Scholar
• Cammenga, J. Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML. Leukemia 19, 1719–1728 (2005).
  Article CAS PubMed Google Scholar
• Huntly, B. J. & Gilliland, D. G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nature Rev. Cancer 5, 311–321 (2005).
  Article CAS Google Scholar
• Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730–737 (1997). Leukaemic C34+CD38 − cells were shown to have preferential capacity to recapitulate leukaemia in a xenograft transplantation model.
  Article CAS PubMed Google Scholar
• Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
  Article CAS PubMed Google Scholar
• Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 5, 738–743 (2004).
  Article CAS Google Scholar
• Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Singh, S. K., Clarke, I. D., Hide, T. & Dirks, P. B. Cancer stem cells in nervous system tumors. Oncogene 23, 7267–7273 (2004).
  Article CAS PubMed Google Scholar
• O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007).
  Article CAS PubMed Google Scholar
• Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104, 973–978 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030–1037 (2007).
  Article CAS PubMed Google Scholar
• Guzman, M. L. et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1, 2, 4-thiadiazolidine, 3, 5 dione (TDZD-8). Blood 110, 4436–4444 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Guzman, M. L. et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110, 4427–4435 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475–482 (2006).
  Article CAS PubMed Google Scholar
• Fialkow, P. J., Jacobson, R. J. & Papayannopoulou, T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 63, 125–130 (1977). A seminal work from 1977 that recognized that CML was a clonal disease.
  Article CAS PubMed Google Scholar
• Udomsakdi, C. et al. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc. Natl Acad. Sci. USA 89, 6192–6196 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Jaiswal, S. et al. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc. Natl Acad. Sci. USA 100, 10002–10007 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Jiang, X., Lopez, A., Holyoake, T., Eaves, A. & Eaves, C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc. Natl Acad. Sci. USA 96, 12804–12809 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Jordan, C. T. & Guzman, M. L. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 23, 7178–7187 (2004).
  Article CAS PubMed Google Scholar
• Copland, M., Hamilton, A. & Holyoake, T. L. Response: Conventional Western blotting techniques will not reliably quantify p210 BCR–ABL. Blood 109, 1336 (2007).
  Article CAS Google Scholar
• Jiang, X. et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR–ABL targeted therapies. Leukemia 21, 926–935 (2007).
  Article CAS PubMed Google Scholar
• Chu, S. et al. Detection of BCR–ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105, 2093–2098 (2005).
  Article CAS PubMed Google Scholar
• Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293, 876–880 (2001).
  Article CAS PubMed Google Scholar
• Jorgensen, H. G. et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19, 1184–1191 (2005).
  Article CAS PubMed Google Scholar
• Copland, M. et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 107, 4532–4539 (2006).
  Article CAS PubMed Google Scholar
• Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319–325 (2002).
  Article CAS PubMed Google Scholar
• Copland, M., Fraser, A. R., Harrison, S. J. & Holyoake, T. L. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunol. Immunother. 54, 297–306 (2005).
  Article CAS PubMed Google Scholar
• Copland, M., Jorgensen, H. G. & Holyoake, T. L. Evolving molecular therapy for chronic myeloid leukaemia — are we on target? Hematology 10, 349–359 (2005).
  Article CAS PubMed Google Scholar
• Deininger, M. et al. No evidence for persistence of BCR–ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia. Blood 96, 779–780 (2000).
  Article CAS PubMed Google Scholar
• Shah, N. P. et al. Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).
  Article CAS PubMed Google Scholar
• Al-Ali, H. K. et al. High incidence of BCR–ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol. J. 5, 55–60 (2004).
  Article CAS PubMed Google Scholar
• Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR–ABL. Cell 112, 831–843 (2003).
  Article CAS PubMed Google Scholar
• Corbin, A. S., La Rosee, P., Stoffregen, E. P., Druker, B. J. & Deininger, M. W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101, 4611–4614 (2003).
  Article CAS PubMed Google Scholar
• Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236–4243 (2002).
  CAS PubMed Google Scholar
• Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938–1942 (2000).
  Article CAS PubMed Google Scholar
• Morel, F. et al. Double minutes containing amplified BCR–ABL fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur. J. Haematol. 70, 235–239 (2003).
  Article PubMed Google Scholar
• Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).
  Article CAS PubMed Google Scholar
• Bartholomeusz, G. A. et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109, 3470–3478 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Cong, P. et al. IPI-504, a novel, orally active HSP90 inhibitor, prolongs survival of mice with BCR–ABL T315I CML and B-ALL. Blood 108, Abstract 2183 (2006).
  Article Google Scholar
• Giles, F. J. et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR–ABL mutation. Blood 109, 500–502 (2007).
  Article CAS PubMed Google Scholar
• Harrington, E. A. et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Med. 10, 262–267 (2004).
  Article CAS PubMed Google Scholar
• O'Hare, T. et al. Inhibition of T315I BCR–ABL and other imatinib-resistant BCR–ABL mutants by the selective ABL kinase inhibitor SGX70393. Blood 108, Abstract 1373 (2006).
  Article Google Scholar
• Shakespeare, W. et al. Orally active inhibitors of the imatinib resistant BCR–ABL mutant T315I. Blood 108, Abstract 2180 (2006).
• White, D. L. et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108, 697–704 (2006).
  Article CAS PubMed Google Scholar
• White, D. et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106, 2520–2526 (2005).
  Article CAS PubMed Google Scholar
• Danhauser-Riedl, S., Warmuth, M., Druker, B. J., Emmerich, B. & Hallek, M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 56, 3589–3596 (1996).
  CAS PubMed Google Scholar
• Donato, N. J. et al. BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690–698 (2003).
  Article CAS PubMed Google Scholar
• Wilson, M. B., Schreiner, S. J., Choi, H. J., Kamens, J. & Smithgall, T. E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis. Oncogene 21, 8075–8088 (2002).
  Article CAS PubMed Google Scholar
• Michor, F. et al. Dynamics of chronic myeloid leukaemia. Nature 435, 1267–1270 (2005).
  Article CAS PubMed Google Scholar
• Jordanides, N. E., Jorgensen, H. G., Holyoake, T. L. & Mountford, J. C. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108, 1370–1373 (2006).
  Article CAS PubMed Google Scholar
• Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
  Article CAS PubMed Google Scholar
• Radich, J. P. et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl Acad. Sci. USA (2006). An important recent microarray analysis of the genes upregulated in different phases of CML, which highlights the presence of variable genetic signatures in different phases of the disease.
• Roeder, I. et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nature Med. 12, 1181–1184 (2006).
  Article CAS PubMed Google Scholar
• Weinstein, I. B. et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin. Cancer Res. 3, 2696–2702 (1997).
  CAS PubMed Google Scholar
• Weinstein, I. B. Cancer. Addiction to oncogenes — the Achilles heal of cancer. Science 297, 63–64 (2002).
  Article CAS PubMed Google Scholar
• Sharma, S. V., Fischbach, M. A., Haber, D. A. & Settleman, J. “Oncogenic shock”: explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 12, 4392s–4395s (2006).
  Article CAS PubMed Google Scholar
• Sharma, S. V. et al. A common signaling cascade may underlie “addiction” to the Src, BCR–ABL, and EGF receptor oncogenes. Cancer Cell 10, 425–435 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Chu, S., Holtz, M., Gupta, M. & Bhatia, R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103, 3167–3174 (2004).
  Article CAS PubMed Google Scholar
• Deacon, K., Mistry, P., Chernoff, J., Blank, J. L. & Patel, R. p38 mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol. Biol. Cell 14, 2071–2087 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Losa, J. H. et al. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 22, 3998–4006 (2003).
  Article CAS Google Scholar
• Puri, P. L. et al. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev. 14, 574–584 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Lahaye, T. et al. Response and resistance in 300 patients with BCR–ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103, 1659–1669 (2005).
  Article PubMed Google Scholar
• Lange, T., Park, B., Willis, S. G. & Deininger, M. W. BCR–ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle 4, 1761–1766 (2005).
  Article CAS PubMed Google Scholar
• Corey, S. J. et al. Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor. J. Biol. Chem. 273, 3230–3235 (1998).
  Article CAS PubMed Google Scholar
• Donato, N. J. et al. Imatinib mesylate resistance through BCR–ABL independence in chronic myelogenous leukemia. Cancer Res. 64, 672–677 (2004).
  Article CAS PubMed Google Scholar
• Tipping, A. J., Deininger, M. W., Goldman, J. M. & Melo, J. V. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp. Hematol. 31, 1073–1080 (2003).
  Article CAS PubMed Google Scholar
• Walkley, C. R. et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency. Cell 129, 1097–1110 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Walkley, C. R., Shea, J. M., Sims, N. A., Purton, L. E. & Orkin, S. H. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 129, 1081–1095 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Krause, D. S., Lazarides, K., von Andrian, U. H. & Van Etten, R. A. Requirement for CD44 in homing and engraftment of BCR–ABL-expressing leukemic stem cells. Nature Med. 12, 1175–1180 (2006).
  Article CAS PubMed Google Scholar
• Rossi, D. J. et al.Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 447, 725–729 (2007).
  Article CAS PubMed Google Scholar
• Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9. Nature 442, 818–822 (2006). Kristov et al . illustrated the capacity to recapitulate stem cell features in progeny cells by viral transfection of a powerful oncogene.
  Article CAS PubMed Google Scholar
• Huntly, B. J. et al. MOZ–TIF2, but not BCR–ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587–596 (2004).
  Article CAS PubMed Google Scholar
• Cozzio, A. et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17, 3029–3035 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• So, C. W. et al. MLL–GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 3, 161–171 (2003).
  Article CAS PubMed Google Scholar
• Marley, S. B., Deininger, M. W., Davidson, R. J., Goldman, J. M. & Gordon, M. Y. The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp. Hematol. 28, 551–557 (2000).
  Article CAS PubMed Google Scholar
• Gordon, M. Y. et al. Treatment with interferon-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J. Clin. Invest. 102, 710–715 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Somervaille, T. C. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL–AF9 acute myeloid leukemia. Cancer Cell 10, 257–268 (2006).
  Article CAS PubMed Google Scholar
• Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843–850 (2005).
  Article CAS PubMed Google Scholar
• Arce, L., Yokoyama, N. N. & Waterman, M. L. Diversity of LEF/TCF action in development and disease. Oncogene 25, 7492–7504 (2006).
  Article CAS PubMed Google Scholar
• Scheller, M. et al. Hematopoietic stem cell and multilineage defects generated by constitutive β-catenin activation. Nature Immunol. 7, 1037–1047 (2006).
  Article CAS Google Scholar
• Kirstetter, P., Anderson, K., Porse, B. T., Jacobsen, S. E. & Nerlov, C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nature Immunol. 7, 1048–1056 (2006).
  Article CAS Google Scholar
• Lawson, N. D. et al. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 128, 3675–3683 (2001).
  Article CAS PubMed Google Scholar
• Maillard, I., He, Y. & Pear, W. S. From the yolk sac to the spleen: New roles for Notch in regulating hematopoiesis. Immunity 18, 587–589 (2003).
  Article CAS PubMed Google Scholar
• Pui, J. C. et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11, 299–308 (1999).
  Article CAS PubMed Google Scholar
• Ellisen, L. W. et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649–661 (1991).
  Article CAS PubMed Google Scholar
• Park, I. K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302–305 (2003).
  Article CAS PubMed Google Scholar
• Sauvageau, G. et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc. Natl Acad. Sci. USA 91, 12223–12227 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Hess, J. L., Yu, B. D., Li, B., Hanson, R. & Korsmeyer, S. J. Defects in yolk sac hematopoiesis in _Mll_-null embryos. Blood 90, 1799–1806 (1997).
  Article CAS PubMed Google Scholar
• Ernst, P. et al. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev. Cell 6, 437–443 (2004).
  Article CAS PubMed Google Scholar
• Steidl, U. et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nature Genet. 38, 1269–1277 (2006).
  Article CAS PubMed Google Scholar
• Lessard, J. & Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255–260 (2003).
  Article CAS PubMed Google Scholar
• Mansour, M. R., Linch, D. C., Foroni, L., Goldstone, A. H. & Gale, R. E. High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia 20, 537–539 (2006).
  Article CAS PubMed Google Scholar
• Tohda, S., Kogoshi, H., Murakami, N., Sakano, S. & Nara, N. Diverse effects of the Notch ligands Jagged1 and Delta1 on the growth and differentiation of primary acute myeloblastic leukemia cells. Exp. Hematol. 33, 558–563 (2005).
  Article CAS PubMed Google Scholar
• Sengupta, A. et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 21, 949–955 (2007).
  Article CAS PubMed Google Scholar
• Aguirre-Ghiso, J. A., Ossowski, L. & Rosenbaum, S. K. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 64, 7336–7345 (2004).
  Article CAS PubMed Google Scholar
• Pruitt, K., Pruitt, W. M., Bilter, G. K., Westwick, J. K. & Der, C. J. Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation. J. Biol. Chem. 277, 31808–31817 (2002).
  Article CAS PubMed Google Scholar
• Molofsky, A. V. et al. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425, 962–967 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Voncken, J. W. et al. MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J. Biol. Chem. 280, 5178–5187 (2005).
  Article CAS PubMed Google Scholar
• Mohty, M., Yong, A. S., Szydlo, R. M., Apperley, J. F. & Melo, J. V. The polycomb group BMI-1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110, 380–383 (2007).
  Article CAS PubMed Google Scholar
• Melo, J. V. & Barnes, D. J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Rev. Cancer 7, 441–453 (2007).
  Article CAS Google Scholar
• Angstreich, G. R. et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br. J. Haematol. 130, 373–381 (2005).
  Article CAS PubMed Google Scholar
• Talpaz, M. et al. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J. Clin. Invest. 94, 1383–1389 (1994). A PCR analysis illustrating the presence of dormant leukaemic progenitors in an interferon-α -induced remission, and thereby suggesting a role of induced immunosurvellience, rather than eradication of CML, with interferon-α therapy.
  Article CAS PubMed PubMed Central Google Scholar
• Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58–60 (2007). Use of imatinib after previous interferon-α treatment resulted in long-term responses without any type of maintenance therapy. This raised the question of potentially reevaluating the use of interferon-α in modern treatment of CML.
  Article CAS PubMed Google Scholar